#LPCN hashtag - Bluesky

@tickerade.bsky.social

1 hour ago

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 36
$AMZN: 23
$META: 15
$SPX: 12
$INTC: 9
$QQQ: 9
$NBIS: 8
$MSFT: 7
$SNBR: 7
$TSLA: 7
$BB: 7
$DVLT: 7
$ARAI: 7
$GOOGL: 6
$GLMD: 6
$LPCN: 6
$ASTS: 6
$ETH: 6

0 0 0 0

tickerade

@tickerade.bsky.social

23 hours ago

$LPCN insider activity heats up with CEO Higuchi buying in, following smart money

0 0 0 0

StockTitan

@stocktitan.net

1 week ago

Oral postpartum depression drug falls short in Phase 3 but shows clean safety In a 54-patient subgroup with psychiatric history, LPCN 1154 showed nominal benefit by hour 12. Lipocine seeks FDA designations and weighs next steps.

#LPCN Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

www.stocktitan.net/news/LPCN/lipocine-repor...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine (NASDAQ: LPCN) reported full-year 2025 results and a corporate update on March 10, 2026. Key financials: $14.9M cash at Dec 31, 2025, $2.0M revenue, and a $9.6M net loss for 2025. Cash later increased to $24.7M as of March 6, 2026 due to an ATM offering.Clinical highlights include completion of Last Patient/Last Visit for the confirmatory Phase 3 study of LPCN 1154 in PPD in Feb 2026, topline results expected early April 2026, and potential 505(b)(2) NDA submission mid-2026 if successful. Development continues across LPCN 2201, 2101 and 2401.

#LPCN Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone Lipocine (NASDAQ: LPCN) announced that its Phase 3 trial of LPCN 1154 for postpartum depression has reached 80% enrollment, with 66 of 80 planned participants randomized as of Dec. 16, 2025. The company said topline results remain on track for Q2 2026.The release notes a prior Data Safety Monitoring Board review that recommended the trial continue without modification and that a second DSMB meeting is planned for early January 2026.

#LPCN Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

www.stocktitan.net/news/LPCN/lipocine-s-ppd...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Power Metallic (TSXV: PNPN) reported results from its 2025 summer drill campaign and spring Lion zone program, including a total of 17,250 metres drilled across multiple targets and five returned Lion holes.Key assay highlights: PML-25-015 returned 28.00 m @ 4.28% CuEq (including 1.90 m @ 17.68% CuEq); PML-25-020 returned 22.66 m @ 4.57% CuEq including 6.05 m @ 9.70% CuEq; PML-25-014 intersected 9.44 m @ 1.01–1.46% CuEq in the disseminated zone. All drilled holes hit sulphide-bearing structures and many received BHEM surveys. The company also bid on newly available Quebec lands and expects bid registration within 30–90 days.

#LPCN Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

www.stocktitan.net/news/LPCN/lipocine-highl...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

#LPCN Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® Lipocine (NASDAQ: LPCN) presented Phase 2 clinical data for oral LPCN 2401 at ObesityWeek® (Nov 4–7, 2025). The poster reports 20‑ and 36‑week results showing increases in lean mass, reductions in fat mass and improved FM/LM ratio versus placebo. LPCN 2401 and LPCN 2401+vitamin E produced rapid liver benefits (ALT/AST reductions starting at 4–8 weeks) and significant MRI‑PDFF liver fat reductions by 12 weeks that were maintained through week 36. LPCN 2401 was reported as well tolerated with no concerning safety signals through 72 weeks.

#LPCN Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

www.stocktitan.net/news/LPCN/lipocine-prese...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) Lipocine (NASDAQ: LPCN) reported progress in its pivotal Phase 3 clinical trial for LPCN 1154, an oral brexanolone treatment for postpartum depression (PPD). The trial has reached a significant milestone with one-third of planned patients randomized, and topline results are expected in Q2 2026.The company plans to provide a safety update in Q4 2025 following a Data Safety Monitoring Board (DSMB) review. The trial is being conducted in an outpatient setting without required medical monitoring, following FDA feedback. LPCN 1154 features a 48-hour dosing schedule and aims to provide rapid, meaningful clinical benefits. Lipocine plans to submit a 505(b)(2) NDA in 2026.

#LPCN Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

www.stocktitan.net/news/LPCN/lipocine-provi...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Lipocine to Showcase Groundbreaking Research at H.C. Wainwright Conference Lipocine Inc. will present innovative drug development strategies at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025.

Lipocine to Showcase Groundbreaking Research at H.C. Wainwright Conference #United_States #Salt_Lake_City #Lipocine #LPCN #Brexanolone

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 SALT LAKE CITY, Aug. 26, 2025/ PRNewswire/-- Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025 American Epilepsy Society annual meeting to be held...

#LPCN Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Lipocine Reports 29% Smaller Loss as PPD Drug Trial Progresses, Targets $70B GLP-1 Market Q2 earnings show improved financials while Phase 3 PPD drug trial advances. New obesity treatment program targets GLP-1 market opportunity. See full pipeline updates.

#LPCN Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Revolutionary Oral Postpartum Depression Treatment Enters Phase 3 Trial - Could Change Standard of Care First patient dosed in pivotal trial of oral PPD treatment LPCN 1154. Novel 48-hour dosing could revolutionize postpartum depression care. See trial design details.

#LPCN Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success Novel oral testosterone therapy targets 700K annual prescriptions in Canada. First-in-class treatment requires no dose adjustment. Learn expansion timeline.

#LPCN Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Breakthrough Cirrhosis Treatment Gets Major Recognition: Phase 2 Results Show Promise in Hepatology Journal FDA Fast-Tracked cirrhosis drug shows promising Phase 2 results for muscle loss treatment. See complete trial data and expert analysis in Hepatology journal. Learn more.

#LPCN Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

www.stocktitan.net/news/LPCN/lipocine-s-lpc...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 Lipocine Inc. (NASDAQ: LPCN) reported Q1 2025 financial results and provided corporate updates. The company ended Q1 with $19.7 million in cash and equivalents, down from $21.6M in Q4 2024. Lipocine posted a net loss of $1.9 million ($0.35/share) compared to net income of $3.5M ($0.66/share) in Q1 2024. Key developments include: initiating Phase 3 study of LPCN 1154 for postpartum depression with first patient dosing expected in Q2 2025; advancing LPCN 2401 for obesity management as an adjunct to GLP-1 therapies; and expanding TLANDO partnerships with Aché for Brazilian market rights. Revenue declined with $94,000 in TLANDO royalties vs. $117,000 in Q1 2024, while R&D expenses decreased to $1.1M from $2.8M, and G&A expenses dropped to $1.1M from $1.6M year-over-year.

#LPCN Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Lipocine Targets Booming Brazil Testosterone Market with Exclusive TLANDO License Deal as Growth Hits 34% Lipocine partners with Aché for TLANDO in Brazil's fast-growing testosterone market. First oral therapy potential, 34% CAGR opportunity. See deal terms.

#LPCN Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase New oral treatment could transform postpartum depression care with convenient at-home administration. Phase 3 trial marks crucial milestone. Full analysis inside.

#LPCN Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results Lipocine reports profitable 2024 with $11.2M revenue from licensing deals, advances oral brexanolone program, and maintains $21.6M cash position. Fast Track status boosts pipeline.

#LPCN Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine FDA eliminates cardiovascular risk box warning for testosterone products, boosting Lipocine's therapy portfolio spanning obesity, liver cirrhosis, and metabolic disorders.

#LPCN Lipocine Announces FDA Labeling Changes for Testosterone Products

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Postpartum Depression Treatment Faces Critical FDA Hurdle: What's Next for Oral Alternative? FDA mandates new efficacy study for LPCN 1154, extending timeline for Lipocine's oral postpartum depression treatment. Company sees opportunity for expanded labeling and exclusivity.

#LPCN Lipocine Receives Updated Regulatory Guidance on LPCN 1154

www.stocktitan.net/news/LPCN/lipocine-recei...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lipocine's LPCN 1148 Secures FDA Fast Track Status for Groundbreaking Sarcopenia Treatment in Cirrhosis Lipocine advances LPCN 1148 with FDA Fast Track Designation following promising Phase 2 results. Potential first-in-class therapy for sarcopenia in cirrhosis patients.

#LPCN FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

www.stocktitan.net/news/LPCN/fda-grants-fas...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#LPCN Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

www.stocktitan.net/news/LPCN/lipocine-annou...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #LPCN ) Lipocine Inc. (NASDAQ: LPCN) Highlighted for Surprising Price Action

#StockMarket #News

1 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #LPCN ) Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries

#StockMarket #News

1 0 0 0